e-ISSN: Pending
Negative / Null Result ReportOpen accessMedicine· cited by 9

Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials

Guiomar Mendieta; Paul M. Ridker; Barry A. Borlaug; Anique Ducharme; Carolyn S.P. Lam; Adriaan A. Voors; Pernille Auerbach; Maja Čikeš · 2026 · European Journal of Heart Failure

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

AIMS: We hypothesized that targeting interleukin-6-a cytokine central to NOD-like receptor protein 3 (NLRP3) inflammasome activation that is associated with both the onset and progression of heart failure (HF)-may be beneficial in patients with HF and circulating evidence of cardiovascular inflammation but without overtly reduced ejection fraction (EF). We describe the rationale and design of two clinical trials (ATHENA and HERMES) investigating ziltivekimab, a human monoclonal antibody directed against the interleukin-6 ligand, in patients with HF and mildly reduced or preserved EF (HFmrEF/HF

Abstract by Guiomar Mendieta; Paul M. Ridker; Barry A. Borlaug; Anique Ducharme; Carolyn S.P. Lam; Adriaan A. Voors; Pernille Auerbach; Maja Čikeš, European Journal of Heart Failure (2026) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1093/ejhf/xuag153